Literature DB >> 2839387

Interaction of sulfonylureas with pancreatic beta-cells. A study with glyburide.

F K Gorus1, F C Schuit, P A In't Veld, W Gepts, D G Pipeleers.   

Abstract

In this study on purified rat pancreatic beta-cells, we show that the second-generation sulfonylurea glyburide stimulates insulin release through a direct interaction with the beta-cells. During static incubations, 2 microM glyburide releases 0.16 pg insulin per beta-cell, which corresponds to a half-maximal glucose stimulation. This effect occurs independently from the glucose-recognition unit, being detectable at both nonstimulatory and stimulatory glucose concentrations and proceeding without alterations in the rate of glucose oxidation. The secretagogue action of glyburide appears not to be mediated through cAMP but is potentiated by cAMP-generating substances such as glucagon (10(-8) M; 0.31 pg insulin released per beta-cell). Its 10-fold higher potency in isolated islets is attributed to the markedly higher cAMP levels that are maintained in islet beta-cells under the influence of locally released glucagon. Perifused pancreatic beta-cells respond to glyburide with a biphasic insulin release. After removal of the drug, the cells continue to secrete insulin at the same rate for greater than or equal to 30 min. This prolonged secretory activity coincides with a cellular accumulation of the drug, primarily in association with membranes of secretory vesicles and mitochondria. Tolbutamide also stimulates insulin release from pure beta-cells, but it is less powerful on a molar basis and does not lead to a sustained hormone release after its removal from the extracellular medium. We conclude that the hypoglycemic action of glyburide is at least partly the result of a direct interaction with pancreatic beta-cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839387     DOI: 10.2337/diab.37.8.1090

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

1.  Tolbutamide-sensitivity of the adenosine 5'-triphosphate-dependent K+ channel in mouse pancreatic B-cells.

Authors:  U Panten; C Heipel; F Rosenberger; K Scheffer; B J Zünkler; C Schwanstecher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-11       Impact factor: 3.000

2.  Elevation of transcription factor Islet-1 levels in vivo increases β-cell function but not β-cell mass.

Authors:  Jingxuan Liu; Erik R Walp; Catherine Lee May
Journal:  Islets       Date:  2012-05-01       Impact factor: 2.694

3.  Chronic exposure to glibenclamide impairs insulin secretion in isolated rat pancreatic islets.

Authors:  D Gullo; A M Rabuazzo; M Vetri; C Gatta; C Vinci; M Buscema; R Vigneri; F Purrello
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

4.  Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level.

Authors:  C Alarcon; B Wicksteed; C J Rhodes
Journal:  Diabetologia       Date:  2006-10-20       Impact factor: 10.122

5.  Tolbutamide potentiates the volume-regulated anion channel current in rat pancreatic beta cells.

Authors:  L Best; S Davies; P D Brown
Journal:  Diabetologia       Date:  2004-11-24       Impact factor: 10.122

6.  Foxa2 regulates multiple pathways of insulin secretion.

Authors:  Kristen A Lantz; Marko Z Vatamaniuk; John E Brestelli; Joshua R Friedman; Franz M Matschinsky; Klaus H Kaestner
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

7.  Microcapsules and transdermal patch: a comparative approach for improved delivery of antidiabetic drug.

Authors:  Manoj K Mishra; Debajyoti Ray; Bhakti B Barik
Journal:  AAPS PharmSciTech       Date:  2009-07-23       Impact factor: 3.246

8.  Glibenclamide activates translation in rat pancreatic beta cells through calcium-dependent mTOR, PKA and MEK signalling pathways.

Authors:  Q Wang; H Heimberg; D Pipeleers; Z Ling
Journal:  Diabetologia       Date:  2008-05-21       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.